Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Osteoarthritis Pain-Pipeline Review, H1 2015

Osteoarthritis Pain-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Osteoarthritis Pain-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Osteoarthritis Pain-Pipeline Review, H1 2015', provides an overview of the Osteoarthritis Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Osteoarthritis Pain pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Osteoarthritis Pain Overview 8

Therapeutics Development 9

Pipeline Products for Osteoarthritis Pain-Overview 9

Pipeline Products for Osteoarthritis Pain-Comparative Analysis 10

Osteoarthritis Pain-Therapeutics under Development by Companies 11

Osteoarthritis Pain-Therapeutics under Investigation by Universities/Institutes 15

Osteoarthritis Pain-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Osteoarthritis Pain-Products under Development by Companies 20

Osteoarthritis Pain-Products under Investigation by Universities/Institutes 23

Osteoarthritis Pain-Companies Involved in Therapeutics Development 24

AbbVie Inc. 24

Actavis plc 25

Addex Therapeutics Ltd 26

Afferent Pharmaceuticals, Inc. 27

Akron Molecules AG 28

Amgen Inc. 29

Ampio Pharmaceuticals, Inc. 30

AnaMar AB 31

Antibe Therapeutics, Inc. 32

Astellas Pharma Inc. 33

Boehringer Ingelheim GmbH 34

Bone Medical Limited 35

Eli Lilly and Company 36

Flexion Therapeutics, Inc. 37

Grunenthal GmbH 38

iCeutica, Inc. 39

Iroko Pharmaceuticals, LLC 40

Nektar Therapeutics 41

Nuvo Research Inc. 42

Pfizer Inc. 43

Phosphagenics Limited 44

Pozen, Inc. 45

Purdue Pharma L.P. 46

Regeneron Pharmaceuticals, Inc. 47

Rottapharm SpA 48

Teva Pharmaceutical Industries Limited 49

Osteoarthritis Pain-Therapeutics Assessment 50

Assessment by Monotherapy Products 50

Assessment by Combination Products 51

Assessment by Target 52

Assessment by Mechanism of Action 55

Assessment by Route of Administration 57

Assessment by Molecule Type 59

Drug Profiles 61

(lidocaine + tetracaine)-Drug Profile 61

A-889425-Drug Profile 63

AAT-008-Drug Profile 64

ADX-71441-Drug Profile 65

AF-219-Drug Profile 66

AKR-202-Drug Profile 68

AMAP-102-Drug Profile 69

Ampion-Drug Profile 71

AQU-010-Drug Profile 73

AS-288640100-Drug Profile 74

ATB-346-Drug Profile 75

BI-1026706-Drug Profile 77

calcitonin-Drug Profile 78

cebranopadol-Drug Profile 80

celecoxib-Drug Profile 82

CGS-125-Drug Profile 83

CRB-0022-Drug Profile 84

CRB-0089-Drug Profile 85

duloxetine hydrochloride DR-Drug Profile 86

ELS-130-Drug Profile 88

fasinumab-Drug Profile 89

fulranumab-Drug Profile 91

FX-005-Drug Profile 94

grapiprant-Drug Profile 95

ibuprofen-Drug Profile 97

ibuprofen-Drug Profile 98

LY-2951742-Drug Profile 99

meloxicam-Drug Profile 101

naproxen sodium-Drug Profile 103

NEO-5024-Drug Profile 105

NEO-6860-Drug Profile 106

NKTR-181-Drug Profile 107

OLT-1177-Drug Profile 109

onabotulinumtoxin A-Drug Profile 110

oxycodone ER-Drug Profile 112

PA-300-Drug Profile 114

PA-300 DR-Drug Profile 116

PA-65020-Drug Profile 117

Small Molecules to Block Calcium Ion Channel for Osteoarthritis Pain-Drug Profile 118

Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation-Drug Profile 119

Small Molecules to Inhibit PDE2 for Osteoarthritis Pain-Drug Profile 120

tanezumab-Drug Profile 121

triamcinolone acetonide sodium phosphate SR-Drug Profile 123

TV-45070-Drug Profile 124

V-116517-Drug Profile 125

VLNX-4975-Drug Profile 126

Osteoarthritis Pain-Recent Pipeline Updates 127

Osteoarthritis Pain-Dormant Projects 156

Osteoarthritis Pain-Discontinued Products 161

Osteoarthritis Pain-Product Development Milestones 163

Featured News & Press Releases 163

Appendix 170

Methodology 170

Coverage 170

Secondary Research 170

Primary Research 170

Expert Panel Validation 170

Contact Us 170

Disclaimer 171

List of Tables

Number of Products under Development for Osteoarthritis Pain, H1 2015 12

Number of Products under Development for Osteoarthritis Pain-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Comparative Analysis by Unknown Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Osteoarthritis Pain-Pipeline by AbbVie Inc., H1 2015 27

Osteoarthritis Pain-Pipeline by Actavis plc, H1 2015 28

Osteoarthritis Pain-Pipeline by Addex Therapeutics Ltd, H1 2015 29

Osteoarthritis Pain-Pipeline by Afferent Pharmaceuticals, Inc., H1 2015 30

Osteoarthritis Pain-Pipeline by Akron Molecules AG, H1 2015 31

Osteoarthritis Pain-Pipeline by Amgen Inc., H1 2015 32

Osteoarthritis Pain-Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 33

Osteoarthritis Pain-Pipeline by AnaMar AB, H1 2015 34

Osteoarthritis Pain-Pipeline by Antibe Therapeutics, Inc., H1 2015 35

Osteoarthritis Pain-Pipeline by Astellas Pharma Inc., H1 2015 36

Osteoarthritis Pain-Pipeline by Boehringer Ingelheim GmbH, H1 2015 37

Osteoarthritis Pain-Pipeline by Bone Medical Limited, H1 2015 38

Osteoarthritis Pain-Pipeline by Eli Lilly and Company, H1 2015 39

Osteoarthritis Pain-Pipeline by Flexion Therapeutics, Inc., H1 2015 40

Osteoarthritis Pain-Pipeline by Grunenthal GmbH, H1 2015 41

Osteoarthritis Pain-Pipeline by iCeutica, Inc., H1 2015 42

Osteoarthritis Pain-Pipeline by Iroko Pharmaceuticals, LLC, H1 2015 43

Osteoarthritis Pain-Pipeline by Nektar Therapeutics, H1 2015 44

Osteoarthritis Pain-Pipeline by Nuvo Research Inc., H1 2015 45

Osteoarthritis Pain-Pipeline by Pfizer Inc., H1 2015 46

Osteoarthritis Pain-Pipeline by Phosphagenics Limited, H1 2015 47

Osteoarthritis Pain-Pipeline by Pozen, Inc., H1 2015 48

Osteoarthritis Pain-Pipeline by Purdue Pharma L.P., H1 2015 49

Osteoarthritis Pain-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 50

Osteoarthritis Pain-Pipeline by Rottapharm SpA, H1 2015 51

Osteoarthritis Pain-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 52

Assessment by Monotherapy Products, H1 2015 53

Assessment by Combination Products, H1 2015 54

Number of Products by Stage and Target, H1 2015 56

Number of Products by Stage and Mechanism of Action, H1 2015 59

Number of Products by Stage and Route of Administration, H1 2015 61

Number of Products by Stage and Molecule Type, H1 2015 63

Osteoarthritis Pain Therapeutics-Recent Pipeline Updates, H1 2015 130

Osteoarthritis Pain-Dormant Projects, H1 2015 159

Osteoarthritis Pain-Dormant Projects (Contd..1), H1 2015 160

Osteoarthritis Pain-Dormant Projects (Contd..2), H1 2015 161

Osteoarthritis Pain-Dormant Projects (Contd..3), H1 2015 162

Osteoarthritis Pain-Dormant Projects (Contd..4), H1 2015 163

Osteoarthritis Pain-Discontinued Products, H1 2015 164

Osteoarthritis Pain-Discontinued Products (Contd..1), H1 2015 165

List of Figures

Number of Products under Development for Osteoarthritis Pain, H1 2015 12

Number of Products under Development for Osteoarthritis Pain-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Products, H1 2015 21

Assessment by Monotherapy Products, H1 2015 53

Number of Products by Top 10 Targets, H1 2015 55

Number of Products by Stage and Top 10 Targets, H1 2015 55

Number of Products by Top 10 Mechanism of Actions, H1 2015 58

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 58

Number of Products by Top 10 Routes of Administration, H1 2015 60

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 61

Number of Products by Top 10 Molecule Types, H1 2015 62

Number of Products by Stage and Top 10 Molecule Types, H1 2015 63

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Actavis plc

Addex Therapeutics Ltd

Afferent Pharmaceuticals, Inc.

Akron Molecules AG

Amgen Inc.

Ampio Pharmaceuticals, Inc.

AnaMar AB

Antibe Therapeutics, Inc.

Astellas Pharma Inc.

Boehringer Ingelheim GmbH

Bone Medical Limited

Eli Lilly and Company

Flexion Therapeutics, Inc.

Grunenthal GmbH

iCeutica, Inc.

Iroko Pharmaceuticals, LLC

Nektar Therapeutics

Nuvo Research Inc.

Pfizer Inc.

Phosphagenics Limited

Pozen, Inc.

Purdue Pharma L.P.

Regeneron Pharmaceuticals, Inc.

Rottapharm SpA

Teva Pharmaceutical Industries Limited

Osteoarthritis Pain Therapeutic Products under Development, Key Players in Osteoarthritis Pain Therapeutics, Osteoarthritis Pain Pipeline Overview, Osteoarthritis Pain Pipeline, Osteoarthritis Pain Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com